Vol. 26/No. 7

Natural language processing models could help streamline processes within clinical settings.

PF-07248144 is a first-in-class selective inhibitor of KAT6A and KAT6B that has displayed the ability to suppress ER expression in a preclinical study.

Sandip P. Patel, MD, discusses targeted therapy combination regimens in EGFR-mutated NSCLC.

In an OncLive Peer Exchange filmed during EBMT, investigators discuss approaches to optimizing allo-HSCT and preventing GVHD in hematologic malignancies.

Maurie Markman, MD, raises concerns about public health priorities and resource allocation in light of the expanding role of precision medicine in cancer.